In a small, preliminary study, an experimental vaccine provoked a strong immune response against precancerous cells in women treated for cervical lesions that can progress to cancer.
Most cases of cervical cancer are caused by infection with two types of human papillomavirus, or HPV. Some women who have precancerous cervical lesions associated with the Type 16 and Type 18 strains of HPV are able to fight them off without medical intervention. They do so by producing high levels of immune cells called killer T-cells.
Read the full story: http://nyti.ms/SQVgeX
Source: The New York Times
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Read More
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More